Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-22
    E.g., 2018-02-22

Articles

8648 items
8:56 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Cell culture and mouse studies suggest inhibiting MENA could help treat metastases of serous ovarian cancer. In a panel of serous ovarian cancer cell lines, expression of the MENA isoform MENAΔv6 was associated...
8:54 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting CHORDC1 could help treat metastatic breast cancer. In patients, high levels of CHORDC1 in primary tumors were associated with tumor invasiveness and poor overall...
8:53 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Bone cancer Patient sample and mouse studies suggest inhibiting tissue factor could help treat metastatic osteosarcoma. In patient tumor samples, levels of histone H3 methylation at an enhancer sequence upstream of the TF gene --...
8:50 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Neurology

INDICATION: Neuropathy Mouse studies suggest inhibiting HDAC3 could help treat peripheral neuropathies. In a mouse model of sciatic nerve injury, tool compound HDAC3 inhibitors increased the number of myelin-producing Schwann cells at the injury site and...
8:50 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Gastric cancer Mouse studies suggest inhibiting IL-4 alone or in combination with IL-13 could help treat gastric cancer. In a mouse model of gastric cancer, systemic double-knockout of IL-4 and IL-13 decreased the number of...
8:50 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Cardiovascular

INDICATION: Heart failure Patient sample, rat and mouse studies suggest inhibiting HDAC2 could help treat diastolic dysfunction. In postmortem myofibrils from heart failure patients, diastolic relaxation time was longer than in matched samples from unaffected donors,...
8:49 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Inflammation; infectious disease

INDICATION: Inflammatory disease; sepsis In vitro and mouse studies suggest inhibiting the MAC-1-CD40L interaction could help treat systemic inflammatory response syndrome (SIRS) and sepsis. In a mouse cell-based assay, a mAb against the M7 motif ligand-binding...
8:49 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Dermatology

INDICATION: Wounds Patient sample and mouse studies suggest CXCL12-secreting Lactobacillus reuteri could help treat wounds. In a human skin biopsy-based model of wound healing, L. reuteri engineered to secrete CXCL12 increased the length of epidermal sleeves...
8:49 AM, Feb 13, 2018  |  BC Innovations | Distillery Therapeutics

Musculoskeletal

INDICATION: Musculoskeletal Frog studies suggest DDX21 mRNA could help treat Treacher Collins syndrome, a craniofacial disorder caused by mutations in the TCOF1 or Pol I genes. In a Xenopus embryo model of the syndrome, injection of...
8:27 AM, Feb 07, 2018  |  BC Innovations | Distillery Therapeutics

Cancer

INDICATION: Lung cancer Cell culture and mouse studies suggest inhibiting RAF1 could help treat KRAS-driven lung cancer. In tumor cells from two patient-derived xenograft (PDX) mouse models of KRAS-driven lung cancer, shRNA targeting RAF1 encoded in...

Pages